Literature DB >> 8463286

High affinity binding, endocytosis, and degradation of conformationally modified albumins. Potential role of gp30 and gp18 as novel scavenger receptors.

J E Schnitzer1, J Bravo.   

Abstract

Scavenger receptors interact with a variety of modified proteins, mediate their endocytosis and degradation, and may play an important role in protein catabolism and pathogenic processes such as atherosclerosis, aging, and diabetes. Many scavenger receptors have been detected kinetically but few such binding proteins have actually been identified. Recently, we found that two membrane-associated proteins, gp30 and gp18, interact more avidly with albumins conformationally modified by chemical means or by surface adsorption to colloidal gold particles than with native albumin. In this study, we show that gp30 and gp18 behave similarly to other known scavenger receptors. Competition studies indicate a similar ligand binding profile to other known scavenger receptors. Polyanionic molecules (dextran sulfate, fucoidan, polyglutamic acid, polyinosinic acid, heparin) and modified albumins such as formaldehyde-treated or maleylated albumin (Mal-bovine serum albumin) competed with albumin conjugated to colloidal gold particles (A-Au) for the blotting of gp30 and gp18. A-Au and Mal-bovine serum albumin bound cultured endothelial cells with high affinity. Modified and native albumins were each internalized, but only modified albumins were then released degraded. Inhibition studies revealed that only the same molecules that were effective in blocking A-Au blotting of gp30 and gp18, also inhibited A-Au degradation. Addition of the lysosomotropic agent chloroquine resulted in more than 70% inhibition of degradation. Differential processing of A-Au by cultured smooth muscle and endothelial cells along with fibroblasts was observed in a manner consistent with gp30 and gp18 expression. Cumulatively, these results suggest that gp30 and gp18 may mediate the high affinity binding, endocytosis, and degradation of conformationally modified albumins but not native albumin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8463286

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Nanoparticle surface charge mediates the cellular receptors used by protein-nanoparticle complexes.

Authors:  Candace C Fleischer; Christine K Payne
Journal:  J Phys Chem B       Date:  2012-07-20       Impact factor: 2.991

2.  Cellular Binding of Anionic Nanoparticles is Inhibited by Serum Proteins Independent of Nanoparticle Composition.

Authors:  Candace C Fleischer; Umesh Kumar; Christine K Payne
Journal:  Biomater Sci       Date:  2013-09-01       Impact factor: 6.843

Review 3.  The inner blood-retinal barrier: Cellular basis and development.

Authors:  Mónica Díaz-Coránguez; Carla Ramos; David A Antonetti
Journal:  Vision Res       Date:  2017-06-27       Impact factor: 1.886

4.  Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.

Authors:  Esben G W Schmidt; Michael L Hvam; Filipa Antunes; Jason Cameron; Dorthe Viuff; Birgitte Andersen; Nanna N Kristensen; Kenneth A Howard
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

5.  2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.

Authors:  Emmanuel S Akinboye; Oliver C Rogers; John T Isaacs
Journal:  Prostate       Date:  2018-03-24       Impact factor: 4.104

Review 6.  Review of the putative cell-surface receptors for alpha-fetoprotein: identification of a candidate receptor protein family.

Authors:  Gerald J Mizejewski
Journal:  Tumour Biol       Date:  2010-12-01

7.  Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin, Ca(2+)-ATPase, and inositol trisphosphate receptor.

Authors:  J E Schnitzer; P Oh; B S Jacobson; A M Dvorak
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Floxuridine Homomeric Oligonucleotides "Hitchhike" with Albumin In Situ for Cancer Chemotherapy.

Authors:  Cheng Jin; Hui Zhang; Jianmei Zou; Yan Liu; Lin Zhang; Fengjie Li; Ruowen Wang; Wenjing Xuan; Mao Ye; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2018-06-19       Impact factor: 15.336

9.  Albumin transcytosis across the epithelium of the lactating mouse mammary gland.

Authors:  Jenifer Monks; Margaret C Neville
Journal:  J Physiol       Date:  2004-08-05       Impact factor: 5.182

10.  Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene.

Authors:  Yun Mo; Micheal E Barnett; Dolores Takemoto; Harriet Davidson; Uday B Kompella
Journal:  Mol Vis       Date:  2007-05-23       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.